Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder

CNS Drugs
Mark Sanford, Lesley J Scott


An intramuscular formulation of the atypical antipsychotic aripiprazole (Abilify) has been developed and is approved in the EU for use in agitation and disturbed behaviour associated with schizophrenia. In the US, it is approved for the treatment of agitation associated with schizophrenia or bipolar I disorder (manic or mixed). In large, well designed trials, intramuscular aripiprazole was an effective and generally well tolerated treatment for agitation associated with schizophrenia, schizoaffective disorder, schizophreniform disorder or bipolar I disorder. Intramuscular aripiprazole was more effective than placebo in these patient populations and was noninferior to intramuscular haloperidol in those with agitation associated with schizophrenia and its related disorders. Aripiprazole is associated with a low risk for extrapyramidal symptoms (EPS), cardiac effects, hyperprolactinaemia, weight gain and other metabolic disturbances. Head-to-head trials comparing intramuscular aripiprazole with other intramuscular atypical antipsychotics are required before the relative position of each of these agents can be fully determined. In the meantime, intramuscular aripiprazole, with its favourable tolerability profile, is a valuable trea...Continue Reading


Sep 16, 2008·CNS Drugs·Juliane WeberLesley J Scott
Apr 7, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeSiegfried Kasper
Feb 13, 2016·Expert Opinion on Pharmacotherapy·Steven G Potkin, Adrian Preda
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanWorld Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Jul 29, 2009·Annals of General Psychiatry·Konstantinos N Fountoulakis, Eduard Vieta
Oct 22, 2011·Expert Review of Neurotherapeutics·Min-Hyeon ParkWolfgang W Fleischhacker
Jan 2, 2010·Annals of General Psychiatry·Konstantinos N FountoulakisFrank Schmidt
Mar 19, 2013·Pharmacotherapy·Sergio De FilippisPaolo Girardi


Jul 20, 2004·Drugs·Tracy Swainston Harrison, Caroline M Perry
May 27, 2005·Drugs·John Battaglia
Jun 9, 2005·Expert Review of Neurotherapeutics·Warren A Kinghorn, Joseph P McEvoy
Sep 8, 2005·Psychosomatics·Neil B SandsonKelly L Cozza

Related Concepts

Metabolic Process, Cellular
Antipsychotic Effect
Atypical Antipsychotic [EPC]
Assay OF Haloperidol
Extrapyramidal Sign
Bipolar Disorder

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.